Research ExplorerPublicationsAntithrombotic management and outcomes of patients with atri...

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry

Standard

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. / Renda, Giulia; Pecen, Ladislav; Patti, Giuseppe; Ricci, Fabrizio; Kotecha, Dipak; Siller-Matula, Jolanta M; Schnabel, Renate B; Wachter, Rolf; Sellal, Jean-Marc; Rohla, Miklos; Lucerna, Markus; Huber, Kurt; Verheugt, Freek W A; Zamorano, Jose Luis; Brüggenjürgen, Bernd; Darius, Harald; Duytschaever, Mattias; Le Heuzey, Jean-Yves; Schilling, Richard J; Kirchhof, Paulus; De Caterina, Raffaele.

In: INTERN EMERG MED, Vol. 16, No. 3, 04.2021, p. 591-599.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Renda, G, Pecen, L, Patti, G, Ricci, F, Kotecha, D, Siller-Matula, JM, Schnabel, RB, Wachter, R, Sellal, J-M, Rohla, M, Lucerna, M, Huber, K, Verheugt, FWA, Zamorano, JL, Brüggenjürgen, B, Darius, H, Duytschaever, M, Le Heuzey, J-Y, Schilling, RJ, Kirchhof, P & De Caterina, R 2021, 'Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry', INTERN EMERG MED, vol. 16, no. 3, pp. 591-599. https://doi.org/10.1007/s11739-020-02442-9

APA

Renda, G., Pecen, L., Patti, G., Ricci, F., Kotecha, D., Siller-Matula, J. M., Schnabel, R. B., Wachter, R., Sellal, J-M., Rohla, M., Lucerna, M., Huber, K., Verheugt, F. W. A., Zamorano, J. L., Brüggenjürgen, B., Darius, H., Duytschaever, M., Le Heuzey, J-Y., Schilling, R. J., ... De Caterina, R. (2021). Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. INTERN EMERG MED, 16(3), 591-599. https://doi.org/10.1007/s11739-020-02442-9

Vancouver

Renda G, Pecen L, Patti G, Ricci F, Kotecha D, Siller-Matula JM et al. Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. INTERN EMERG MED. 2021 Apr;16(3):591-599. https://doi.org/10.1007/s11739-020-02442-9

Bibtex

@article{44da2b24a5864391b37af504b8ae9ae9,
title = "Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry",
abstract = "The management of patients with atrial fibrillation (AF) has rapidly changed with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs) and changes in the use of rhythm control therapy. The prevention of thromboembolic events European Registry in Atrial Fibrillation Prolongation Registry (PREFER Prolongation) enrolled consecutive patients with AF on NOACs between 2014 and 2016 in a multicentre, prospective, observational study with one-year follow-up, focusing on the time of introduction of NOACs. Overall, 3783 patients were enrolled, with follow-up information available in 3223 (85%). Mean age was 72.2 ± 9.4 years, 40% were women, mean CHA2DS2VASc score was 3.4 ± 1.6, and 2587 (88.6%) had a CHA2DS2VASc score ≥ 2. Rivaroxaban was used in half of patients, and dabigatran and apixaban were used in about a quarter of patients each; edoxaban was not available for use in Europe at the time. Major cardiovascular event rate was low: serious events occurred in 74 patients (84 events, 2%), including 24 strokes (1%), 62 major bleeds (2%), of which 30 were life-threatening (1%) and 3 intracranial (0.1%), and 28 acute coronary syndromes (1%). Mortality was 2%. Antiarrhythmic drugs were used in about 50% of patients, catheter ablation in 5%. Adverse events were low in this contemporary European cohort of unselected AF patients treated with NOACs already at the time of their first introduction, despite high thromboembolic risk.",
keywords = "Administration, Oral, Aged, Atrial Fibrillation/drug therapy, Dabigatran/administration & dosage, Europe/epidemiology, Factor Xa Inhibitors/administration & dosage, Female, Humans, Male, Prospective Studies, Pyrazoles/administration & dosage, Pyridones/administration & dosage, Registries, Rivaroxaban/administration & dosage",
author = "Giulia Renda and Ladislav Pecen and Giuseppe Patti and Fabrizio Ricci and Dipak Kotecha and Siller-Matula, {Jolanta M} and Schnabel, {Renate B} and Rolf Wachter and Jean-Marc Sellal and Miklos Rohla and Markus Lucerna and Kurt Huber and Verheugt, {Freek W A} and Zamorano, {Jose Luis} and Bernd Br{\"u}ggenj{\"u}rgen and Harald Darius and Mattias Duytschaever and {Le Heuzey}, Jean-Yves and Schilling, {Richard J} and Paulus Kirchhof and {De Caterina}, Raffaele",
year = "2021",
month = apr,
doi = "10.1007/s11739-020-02442-9",
language = "English",
volume = "16",
pages = "591--599",
journal = "INTERN EMERG MED",
issn = "1828-0447",
publisher = "Springer-Verlag Italia",
number = "3",

}

RIS

TY - JOUR

T1 - Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry

AU - Renda, Giulia

AU - Pecen, Ladislav

AU - Patti, Giuseppe

AU - Ricci, Fabrizio

AU - Kotecha, Dipak

AU - Siller-Matula, Jolanta M

AU - Schnabel, Renate B

AU - Wachter, Rolf

AU - Sellal, Jean-Marc

AU - Rohla, Miklos

AU - Lucerna, Markus

AU - Huber, Kurt

AU - Verheugt, Freek W A

AU - Zamorano, Jose Luis

AU - Brüggenjürgen, Bernd

AU - Darius, Harald

AU - Duytschaever, Mattias

AU - Le Heuzey, Jean-Yves

AU - Schilling, Richard J

AU - Kirchhof, Paulus

AU - De Caterina, Raffaele

PY - 2021/4

Y1 - 2021/4

N2 - The management of patients with atrial fibrillation (AF) has rapidly changed with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs) and changes in the use of rhythm control therapy. The prevention of thromboembolic events European Registry in Atrial Fibrillation Prolongation Registry (PREFER Prolongation) enrolled consecutive patients with AF on NOACs between 2014 and 2016 in a multicentre, prospective, observational study with one-year follow-up, focusing on the time of introduction of NOACs. Overall, 3783 patients were enrolled, with follow-up information available in 3223 (85%). Mean age was 72.2 ± 9.4 years, 40% were women, mean CHA2DS2VASc score was 3.4 ± 1.6, and 2587 (88.6%) had a CHA2DS2VASc score ≥ 2. Rivaroxaban was used in half of patients, and dabigatran and apixaban were used in about a quarter of patients each; edoxaban was not available for use in Europe at the time. Major cardiovascular event rate was low: serious events occurred in 74 patients (84 events, 2%), including 24 strokes (1%), 62 major bleeds (2%), of which 30 were life-threatening (1%) and 3 intracranial (0.1%), and 28 acute coronary syndromes (1%). Mortality was 2%. Antiarrhythmic drugs were used in about 50% of patients, catheter ablation in 5%. Adverse events were low in this contemporary European cohort of unselected AF patients treated with NOACs already at the time of their first introduction, despite high thromboembolic risk.

AB - The management of patients with atrial fibrillation (AF) has rapidly changed with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs) and changes in the use of rhythm control therapy. The prevention of thromboembolic events European Registry in Atrial Fibrillation Prolongation Registry (PREFER Prolongation) enrolled consecutive patients with AF on NOACs between 2014 and 2016 in a multicentre, prospective, observational study with one-year follow-up, focusing on the time of introduction of NOACs. Overall, 3783 patients were enrolled, with follow-up information available in 3223 (85%). Mean age was 72.2 ± 9.4 years, 40% were women, mean CHA2DS2VASc score was 3.4 ± 1.6, and 2587 (88.6%) had a CHA2DS2VASc score ≥ 2. Rivaroxaban was used in half of patients, and dabigatran and apixaban were used in about a quarter of patients each; edoxaban was not available for use in Europe at the time. Major cardiovascular event rate was low: serious events occurred in 74 patients (84 events, 2%), including 24 strokes (1%), 62 major bleeds (2%), of which 30 were life-threatening (1%) and 3 intracranial (0.1%), and 28 acute coronary syndromes (1%). Mortality was 2%. Antiarrhythmic drugs were used in about 50% of patients, catheter ablation in 5%. Adverse events were low in this contemporary European cohort of unselected AF patients treated with NOACs already at the time of their first introduction, despite high thromboembolic risk.

KW - Administration, Oral

KW - Aged

KW - Atrial Fibrillation/drug therapy

KW - Dabigatran/administration & dosage

KW - Europe/epidemiology

KW - Factor Xa Inhibitors/administration & dosage

KW - Female

KW - Humans

KW - Male

KW - Prospective Studies

KW - Pyrazoles/administration & dosage

KW - Pyridones/administration & dosage

KW - Registries

KW - Rivaroxaban/administration & dosage

U2 - 10.1007/s11739-020-02442-9

DO - 10.1007/s11739-020-02442-9

M3 - SCORING: Journal article

C2 - 32955677

VL - 16

SP - 591

EP - 599

JO - INTERN EMERG MED

JF - INTERN EMERG MED

SN - 1828-0447

IS - 3

ER -